AI Software Estimates Heart Blood Flow From CT
Patients evaluated for coronary narrowing may one day avoid an invasive test to measure artery blood flow.
Updated on Nov. 3, 2026 in Heart Disease

Elucid presented a study of its FFR-IQ software at the TCT 2026 conference in San Diego, reporting 92.9% vessel-level diagnostic accuracy compared with invasive fractional flow reserve (FFR). The software, which has recently received FDA 510(k) clearance, estimates FFR from existing coronary CT angiography scans, offering a noninvasive option for people being evaluated for coronary artery disease.
Why it matters
Fractional flow reserve is the standard measure of whether a narrowed coronary artery restricts blood flow enough to need treatment, but it normally requires an invasive catheter procedure. A software tool that estimates this measure from a scan already in use could help clinicians decide who needs further testing or intervention without adding an invasive step for every patient.
The Elucidate study compared FFR-IQ estimates with invasive FFR in 491 coronary vessels from 347 patients at 11 U.S. and European institutions. The software met both primary endpoints, though accuracy fell to 84.1% in the borderline 0.75 to 0.85 FFR range, where clinical judgment is most often needed.
The players
Elucid
A company that develops AI-based software for analyzing coronary CT angiography to assess heart artery disease.
TCT (Transcatheter Cardiovascular Therapeutics) 2026
A major international cardiology conference where interventional cardiology research and devices are presented.
U.S. Food and Drug Administration (FDA)
The U.S. federal agency that reviews and clears medical devices and diagnostic software for market.
The details
FFR-IQ uses a deep-learning model that takes into account coronary anatomy and plaque composition. It applies that model to coronary CT angiography scans that have already been taken, estimating FFR values along each coronary vessel rather than measuring pressure directly inside the artery during a catheter procedure.
Timeline
Study presented at the TCT 2026 conference in San Diego (exact date not specified in the source).
FFR-IQ received FDA 510(k) clearance before the announcement.
Health Landscape
Fractional flow reserve has long been the reference standard for judging whether a coronary narrowing is functionally significant, and most clinicians obtain it through invasive catheterization. Noninvasive estimates derived from CT angiography aim to reduce the number of patients who need that procedure just to answer that question.
If you have had a coronary CT angiogram, this kind of software may eventually help your care team decide whether further testing is needed without an additional invasive procedure. Ask your cardiologist whether noninvasive FFR estimates are available where you are treated and whether they would be useful in your situation.
The takeaway
Noninvasive estimates of coronary blood-flow measures are moving closer to routine use, and the accuracy data here are encouraging but come from one company's study. Readers with coronary artery concerns should discuss with their physician which tests are appropriate for them.
Further reading
For more background on the condition this software is designed to assess, see our Heart Disease coverage.
Source note: This article includes information reported by AuntMinnie.


